Veradigm Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Dati insufficienti per determinare lo stato di salute di Veradigm

Informazioni chiave

n/a

Rapporto debito/patrimonio netto

n/a

Debito

Indice di copertura degli interessi	n/a
Contanti	n/a
Patrimonio netto	n/a
Totale passività	n/a
Totale attività	n/a

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 22

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Jan 04

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Dec 03

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Sep 28

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Sep 17

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Aug 24

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Jul 31

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Jun 15

We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)

May 03

Analisi della posizione finanziaria

Passività a breve termine: Dati insufficienti per determinare se le attività a breve termine di MDRX coprono le sue passività a breve termine.

Passività a lungo termine: Dati insufficienti per determinare se le attività a breve termine di MDRX coprono le sue passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Dati insufficienti per calcolare il rapporto debito netto/patrimonio netto di MDRX per determinare se è soddisfacente.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di MDRX si sia ridotto negli ultimi 5 anni.

Copertura del debito: Dati insufficienti per determinare se il debito di MDRX è ben coperto dal flusso di cassa operativo.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di MDRX siano ben coperti dall'EBIT.

Veradigm Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Veradigm Inc. announced delayed 10-Q filing

Veradigm Inc. announced delayed 10-Q filing

Veradigm Inc. announced delayed 10-Q filing

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from Listing

Veradigm Inc. announced delayed annual 10-K filing

Veradigm Receives Expected Delisting Notice from Nasdaq

Recent updates

Veradigm Inc. announced delayed 10-Q filing

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

Veradigm Inc. announced delayed 10-Q filing

Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic Collaboration

Veradigm Inc. Is Reaffirms Earnings Guidance for Fiscal 2024

Veradigm Inc. Announces Interim Chief Executive Officer Changes

Veradigm Inc. announced delayed 10-Q filing

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from Listing

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Veradigm Inc. (OTCPK:MDRX) completed the acquisition of Cascade Bio, Inc

Veradigm Inc. announced delayed annual 10-K filing

Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite Index

Veradigm Receives Expected Delisting Notice from Nasdaq

Investor sentiment deteriorates as stock falls 18%

Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Robbins Geller Rudman & Dowd LLP Files Amended Class Action Lawsuit Against Veradigm Inc

Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm Inc

Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

Veradigm Inc. Announces CEO Changes

Veradigm Inc. Announces CEO Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q

Veradigm Inc. announced delayed 10-Q filing

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Veradigm to Simplify Patient Payment Journey with Veradigm Intelligent Payments

Veradigm Inc. Announces Receipt of Nasdaq Stay Extension

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Veradigm Inc. announced delayed 10-Q filing

Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)

Veradigm Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Veradigm Inc. announced delayed 10-Q filing

Price target decreased by 7.1% to US$19.19

Price target decreased by 9.1% to US$20.07

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Investor sentiment deteriorates as stock falls 15%

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Consensus EPS estimates fall by 11%

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Veradigm Inc. to Report Q4, 2022 Results on Feb 23, 2023

LeanTaaS Inc. acquired Hospital IQ, Inc.

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Insider notifies of intention to sell stock

Independent Director recently sold US$797k worth of stock

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS misses analyst expectations

Allscripts Healthcare Solutions, Inc. Provides Revenue Guidance for the Year 2022

Allscripts Healthcare Solutions, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Chief Financial Officer recently sold US$116k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer recently sold US$70k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.16 in 2Q 2021)

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt